Skip to main content
Log in

The effects of L-dopa on the activity of methionine adenosyltransferase: Relevance to L-dopa therapy and tolerance

  • Original Articles
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

L-dopa, the major treatment for Parkinson's disease (PD), depletes S-adenosyl-L-methionine (SAM). Since SAM causes PD-like symptoms in rodents, the decreased efficacy of chronic L-dopa administered to PD patients may result from a rebound increase in SAM via methionine adenosyl transferase (MAT), which produces SAM from methionine and ATP. This was tested by administering intraperitoneally saline, or L-dopa to mice and assaying for brain MAT activity. As compared to controls, L-dopa (100 mg/kg) treatments of 1 and 2 times per day for 4 days did not significantly increase MAT activity. However, treatments of 1 and 2 times per day for 4 and 8 days did significantly increase the activity of MAT by 21.38% and 28.37%, respectively. These results show that short interval, chronic L-dopa treatments significantly increases MAT activity, which increases the production of SAM. SAM may physiologically antagonize the effects of L-dopa and biochemically decrease the concentrations of L-dopa and dopamine. Thus, an increase in MAT may be related to the decreased efficacy of chronic L-dopa therapy in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barbeau, A. 1986. Extrapyramidal Disorders, Pages 87–152,in Vinken, P. J., Bruyn, G. W., and Klawans, H. L., (eds.) Handbook of Clinical Neurology, vol. 5(49), Elsevier.

  2. Hefti, F., Melamed, E., and Wurtman, R. J. 1981. The site of dopamine formation in rat striatum after L-dopa administration. J. Pharmacol. Exp. Ther. 217:189–197.

    Google Scholar 

  3. Hornykiewicz, O. 1974. The Mechanisms of Action of L-dopa in Parkinson's Disease. Life Sci. 15:1249–1259.

    Google Scholar 

  4. Mena, M. A., Murandas, V., et al. 1986. Pharmacokinetics of L-dopa in patients with Parkinson's disease. Adv. in Neurol. 45:481–486.

    Google Scholar 

  5. Melamed, E., Globus, M., et al. 1983. Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections. Neurology 33:905–953.

    Google Scholar 

  6. Hunter, K. R., Shaw, K. M., Laurence, D. R., et al. 1973. Sustained levodopa therapy in parkinsonism. Lancet. 2:929–931.

    Google Scholar 

  7. Marsden, C. D., and Parkes, J. D. 1977. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1:345–349.

    Google Scholar 

  8. Fahn, S., and Calne, D. B. 1978. Considerations in the management of parkinsonism. Neurology (NY) 28:5–7.

    Google Scholar 

  9. Barbeau, A. 1969. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can. Med. Assoc. J. 101:791–800.

    Google Scholar 

  10. McDowell, F. H., and Sweet, R. D. 1976. The on-off phenomenon. Pages 603–612.in Birkmayer, W., Hornykiewicz, O., (eds.) Advances in parkinsonism. Basel: Editiones Roche.

    Google Scholar 

  11. Barbeau, A. 1976. Pathophysiology of the oscillations in performance after long-term therapy with L-dopa. Pages 424–434,in Birkmayer, W., and Hornykiewicz, O., (eds.) Advances in parkinsonism. Basel: Editiones Roche.

    Google Scholar 

  12. Ludin, H. P., Bass-Verrey, F. 1976. Study of deterioration in long term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor. J. Neural. Transm. 38:249–258.

    Google Scholar 

  13. Rinne, U. K. 1978. Recent advances in research of parkinsonism. Acta. Neurol. Scand. [Suppl 67] 157:77–113.

    Google Scholar 

  14. Lee, T., Seeman, P., Rajput, A., et al. 1978. Receptor basis for Dopaminergic supersensitivity in Parkinson's disease. Nature 273:59–61.

    Google Scholar 

  15. Reisine, T. D., Fields, J. Z., Yamamura, H. J., et al. 1977. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci. 21:335–344.

    Google Scholar 

  16. Rinne, U. K. 1981. Treatment of Parkinson's disease: problems with a progressing disease. J. Neural. Transm. 51:161–174.

    Google Scholar 

  17. Creese, I., and Sibley, D. R. 1981. Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol. 21:357–391.

    Google Scholar 

  18. Klawans, H. L., Goetz, C., Nausieda, P. A., et al. 1977. Levodopa-induced dopamine receptor supersensitivity. Ann. Neurol. 2:1259.

    Google Scholar 

  19. Sahakian, B. J., Carlson, K. R., DeGirolami, U., et al. 1980. Functional and structural consequences of long-term dietary L-dopa treatment in mice. Commun. Psychopharmacol. 4:169–176.

    Google Scholar 

  20. Suga, M. 1980. Effect of long-term L-dopa administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats. Life Sci. 27:877–882.

    Google Scholar 

  21. Yahr, M. D. 1977. Long-term levodopa in Parkinson's disease. Lancet 1:706–707.

    Google Scholar 

  22. Lesser, R. P., Fahn, S., Snider, S. R., et al. 1979. Analysis of the clinical problems in parkinsonism and the complications of long term levodopa therapy. Neurology (NY) 29:1253–1260.

    Google Scholar 

  23. Weiner, W. J., Koller, W. C., Perlik, S., et al. 1980. Drug holiday and management of Parkinson's disease. Neurology (NY) 30:1257–1261.

    Google Scholar 

  24. Direnfeld, L. K., Feldman, R. G., Alexander, M. P., et al. 1980. Is L-dopa drug holiday useful? Neurology (NY) 30:785–788.

    Google Scholar 

  25. Charlton, C. G., and Way, E. L. 1978. Tremor induced by S-adenosyl methionine: possible relation to L-dopa effects. J. Pharm. Pharmac. 30:819–820.

    Google Scholar 

  26. Axelrod, J., and Tomchick, R. 1958. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233:702–705.

    Google Scholar 

  27. Barbeau, A., et al. 1965. Pharmacology of 3,4-Dimethoxyphenylethylamine. Canad. Med. Ass. J. 92:347.

    Google Scholar 

  28. Wurtman, R. J., and Rose, C. M. 1970. L-dihydroxyphenyl-alanine: effect of S-adenosyl methionine in brain. Science 169:395–397.

    Google Scholar 

  29. Feuerstein, C. I., Tanche, M., Serre, F., et al. 1977. Does O-methyl-dopa play a role in levodopa-induced dyskinesia? Acta Neurol. Scandinav. 56:79–82.

    Google Scholar 

  30. Cantoni, G. L. 1952. The nature of the active methyl donor formed enzymatically from 1-methionine and adenosine triphosphate. J. Am. Chem. Soc. 74:2942–2948.

    Google Scholar 

  31. Mudd, H. S., Finkelstein, J. D., et al. 1965. Trans-sulfuration in mammals: microassays and tissue distributions of three enzymes of the pathway. J. Biol. Chem., vol. 240, 11:4382–4392.

    Google Scholar 

  32. Gharib, A., Sarda, B., et al. 1982. The regional concentration of S-adenosyl-L-methionine, S-adenosyl-L-homocysteine, and adenosine in rat brain. J. Neurochem. 38:810–815.

    Google Scholar 

  33. Cantoni, G. L., Mudd, S. H., and Andreoli, V. 1989. Affective disorders and S-adenosyl methionine: a new hypothesis. TINS 12; 9:319–324.

    Google Scholar 

  34. Charlton, C. 1990. A parallel relationship between Parkinson's disease and an excess of S-adenosyl-L-methionine-dependent biological methylation in the brain. Pages 333–339,in Nagatsu, T., et al. (eds.), Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Vol 1, Plenum Press, New York.

    Google Scholar 

  35. Gancher, S. T., Nutt, J. G., and Woodward, W. 1988. Response to brief levodopa infusions in Parkinsonian patients with and without motor fluctuations. Neurology 38:712–716.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benson, R., Crowell, B., Hill, B. et al. The effects of L-dopa on the activity of methionine adenosyltransferase: Relevance to L-dopa therapy and tolerance. Neurochem Res 18, 325–330 (1993). https://doi.org/10.1007/BF00969090

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00969090

Key Words

Navigation